Open Access. Powered by Scholars. Published by Universities.®

Digital Commons Network

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Entire DC Network

Metabolomic Approach For Earlier Diagnosis Of Cisplatin-Induced Acute Kidney Injury, Steven Xiu, James (Yong Jin) Lim Aug 2022

Metabolomic Approach For Earlier Diagnosis Of Cisplatin-Induced Acute Kidney Injury, Steven Xiu, James (Yong Jin) Lim

Undergraduate Student Research Internships Conference

Cisplatin is a chemotherapeutic agent complicated by its dose-limiting nephrotoxicity. This commonly presents as acute kidney injury (AKI), which is characterized by a reversible decline in kidney function. AKI is currently diagnosed by increased serum creatinine (SCr) levels, but this rise in SCr is delayed limiting diagnosis to when significant renal damage has already occurred. Currently, there are no known biomarkers capable of predicting or diagnosing early-stage cisplatin-induced AKI. Metabolomics was used to identify novel predictive/early diagnostic biomarkers for cisplatin-induced AKI. We hypothesized that differences in metabolic profiles will be able to predict and/or diagnose cisplatin-induced AKI prior to rise …


Methodological Challenges In Pharmacoeconomic Submissions For Cancer Drug Reimbursement In Canada From 2019-2021, Nupur Krishnan Aug 2022

Methodological Challenges In Pharmacoeconomic Submissions For Cancer Drug Reimbursement In Canada From 2019-2021, Nupur Krishnan

Undergraduate Student Research Internships Conference

Cancer is the leading cause of death in Canada, carrying a mortality rate of 1 in 4 Canadians. As new therapeutic options are developed, high drug costs place a huge burden on patients and the healthcare system. Due to budget limitations, not all pharmaceuticals can be publicly funded, so difficult decisions must be made for which drugs are funded and in what contexts. The pan-Canadian Oncology Drug Review (pCODR) evaluates submissions for new oncological pharmaceuticals to make reimbursement recommendations. Comprehensive analyses assessing limitations in recent oncology drug submissions have not yet been performed. The objective of this project, therefore, was …